<DOC>
	<DOCNO>NCT02269215</DOCNO>
	<brief_summary>Safety , tolerability pharmacokinetics BIII 890</brief_summary>
	<brief_title>Single Increasing Doses BIII 890 CL Healthy Young Male Volunteers Healthy Elderly Male Female Volunteers</brief_title>
	<detailed_description />
	<criteria>Participants study healthy male , range 21 50 year age within + 20 % normal weight ( BrocaIndex ) healthy elderly male female , &gt; 60 year age within +25 % normal weight ( BrocaIndex ) In accordance good clinical practice ( GCP ) local legislation volunteer give write informed consent prior admission study Volunteers exclude study result medical examination , laboratory test ECG recording judge investigator differ significantly normal clinical value Volunteers know gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Volunteers diseases central nervous system ( epilepsy ) , central nervous system ( CNS ) trauma medical history psychiatric disorder neurological disorder Volunteers know history relevant orthostatic hypotension , faint spell blackouts Volunteers chronic relevant acute infection Volunteers history allergy/hypersensitivity ( include drug allergy ) deem relevant trial , judge investigator Volunteers take drug long halflife ( ≥ 24 hour ) within least one month less ten halflives respective drug enrolment study Volunteers receive drug could influence result trial week prior start study Volunteers participate another study investigational drug within last two month precede study Volunteers smoke ( &gt; 10 cigarette 3 cigar 3 pipes/day ) Volunteers able refrain smoking study day Volunteers drink 60 g alcohol per day Volunteers dependent drug Volunteers participate excessive physical activity ( e.g . competitive sport ) last week study Volunteers donate blood within last 4 week ( ≥ 100 mL )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>